Literature DB >> 32152920

Long-term PERG monitoring of untreated and treated glaucoma suspects.

Phillip S Gordon1, Maja Kostic1, Pedro F Monsalve1, Giacinto Triolo1, Luri Golubev1, Gabriel Luna1, Lori M Ventura1, William J Feuer1, Vittorio Porciatti2.   

Abstract

PURPOSE: To investigate long-term structural and functional progression of untreated and treated glaucoma suspects (UGS and TGS).
METHODS: Retrospective analysis of serial steady-state pattern electroretinogram (PERG), mean retinal nerve fiber layer thickness (RNFLT), and standard automated perimetry mean deviation (SAP-MD) in UGS (N = 20) and TGS (N = 18). Outcome measures were the rates of change (linear regression slopes) of PERG amplitude, PERG phase, mean RNFLT, and SAP-MD over 9.8 ± 1.3 years (15.6 ± 4.2 visits).
RESULTS: The number of patients with significant (P < 0.05) progression slopes for PERG amplitude, PERG phase, RNFLT, and SAP-MD was, respectively, UGS: 5, 0, 4, 2; TGS: 8, 2, 6, 5. In UGS, outcome measures were not correlated with each other. In TGS, both PERG amplitude and RNFLT were significantly (P < 0.05) correlated with SAP-MD (R ≥ 0.58), while PERG amplitude and RNFLT were not correlated with each other (R = 0.43, P = 0.064). The rate of change of SAP-MD was predicted (P < 0.05) by a linear combination of RNFLT slope and PERG amplitude slope.
CONCLUSIONS: Results substantiate and extend previous results showing that steady-state PERG amplitude progressively decreased over time in a proportion of glaucoma suspects, with relatively steeper slope in TGS compared to UGS. RNFLT progression also had a steeper slope in TGS compared to UGS; however, progressions of PERG amplitude and RNFLT were not significantly correlated. Both PERG progression and RNFLT progression independently contribute to prediction of visual field progression.

Entities:  

Keywords:  Glaucoma suspects; Pattern electroretinogram; Retinal ganglion cell function; Retinal nerve fiber layer thickness

Mesh:

Substances:

Year:  2020        PMID: 32152920      PMCID: PMC7483546          DOI: 10.1007/s10633-020-09760-5

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   2.379


  21 in total

1.  Pattern electroretinogram progression in glaucoma suspects.

Authors:  Lori M Ventura; Iuri Golubev; William J Feuer; Vittorio Porciatti
Journal:  J Glaucoma       Date:  2013-03       Impact factor: 2.503

2.  Normative data for a user-friendly paradigm for pattern electroretinogram recording.

Authors:  Vittorio Porciatti; Lori M Ventura
Journal:  Ophthalmology       Date:  2004-01       Impact factor: 12.079

3.  The effects of aging on the pattern electroretinogram and visual evoked potential in humans.

Authors:  V Porciatti; D C Burr; M C Morrone; A Fiorentini
Journal:  Vision Res       Date:  1992-07       Impact factor: 1.886

4.  Pattern electroretinogram in glaucoma suspects: new findings from a longitudinal study.

Authors:  Sebastian F N Bode; Thomas Jehle; Michael Bach
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-06-16       Impact factor: 4.799

5.  Rates and patterns of macular and circumpapillary retinal nerve fiber layer thinning in preperimetric and perimetric glaucomatous eyes.

Authors:  Jung Hwa Na; Kyung Rim Sung; Seung Hee Baek; Soon Tae Kim; Kilwhan Shon; Jong Jin Jung
Journal:  J Glaucoma       Date:  2015 Apr-May       Impact factor: 2.503

6.  Retinal conduction speed analysis reveals different origins of the P50 and N95 components of the (multifocal) pattern electroretinogram.

Authors:  Michael Bach; Anne-Kathrin Cuno; Michael B Hoffmann
Journal:  Exp Eye Res       Date:  2018-01-31       Impact factor: 3.467

7.  Topographic differences in the age-related changes in the retinal nerve fiber layer of normal eyes measured by Stratus optical coherence tomography.

Authors:  William J Feuer; Donald L Budenz; Douglas R Anderson; Louis Cantor; David S Greenfield; Jonathan Savell; Joel S Schuman; Rohit Varma
Journal:  J Glaucoma       Date:  2011-03       Impact factor: 2.503

8.  Progressive loss of retinal ganglion cell function precedes structural loss by several years in glaucoma suspects.

Authors:  Michael R Banitt; Lori M Ventura; William J Feuer; Eleonore Savatovsky; Gabriel Luna; Olga Shif; Brandon Bosse; Vittorio Porciatti
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-03-28       Impact factor: 4.799

9.  Spectral-Domain OCT: Helping the Clinician Diagnose Glaucoma: A Report by the American Academy of Ophthalmology.

Authors:  Teresa C Chen; Ambika Hoguet; Anna K Junk; Kouros Nouri-Mahdavi; Sunita Radhakrishnan; Hana L Takusagawa; Philip P Chen
Journal:  Ophthalmology       Date:  2018-07-07       Impact factor: 12.079

Review 10.  Pattern electroretinogram in glaucoma.

Authors:  Lori M Ventura; Vittorio Porciatti
Journal:  Curr Opin Ophthalmol       Date:  2006-04       Impact factor: 3.761

View more
  4 in total

1.  1α,25-dihydroxyvitamin D3 protects retinal ganglion cells in glaucomatous mice.

Authors:  Francesca Lazzara; Rosario Amato; Chiara Bianca Maria Platania; Federica Conti; Tsung-Han Chou; Vittorio Porciatti; Filippo Drago; Claudio Bucolo
Journal:  J Neuroinflammation       Date:  2021-09-16       Impact factor: 8.322

2.  Pattern Electroretinogram Parameters Are Associated with Optic Nerve Morphology in Preperimetric Glaucoma after Adjusting for Disc Area.

Authors:  Andrew Tirsi; Vasiliki Gliagias; Julie Moehringer; Derek Orshan; Sofia Tello; Peter Derr; Sung Chul Park; Stephen A Obstbaum; Celso Tello
Journal:  J Ophthalmol       Date:  2021-10-13       Impact factor: 1.909

3.  Steady-State Pattern Electroretinography in Eyes with Glaucoma and High Myopia.

Authors:  Xian Hui Lim; Monisha Esther Nongpiur; Raymond P Najjar; Quan V Hoang; Dan Milea; Chee Wai Wong; Rahat Husain; Hla Myint Htoon; Tin Aung; Shamira Perera; Tina Tzee Ling Wong
Journal:  Clin Ophthalmol       Date:  2021-11-17

Review 4.  Non-invasive electrophysiology in glaucoma, structure and function-a review.

Authors:  Khaldoon O Al-Nosairy; Michael B Hoffmann; Michael Bach
Journal:  Eye (Lond)       Date:  2021-06-11       Impact factor: 3.775

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.